My Life, Our Future pilot phase successfully completed
Initiative aims to offer genotyping to all people affected by the
disorder in the United States
May help improve treatment and care today, and advance future
ANAHEIM, Calif.--(BUSINESS WIRE)--
Today, a coalition of leaders in hemophilia advocacy and treatment
announced the national rollout of My
Life, Our Future: Genotyping for Progress in Hemophilia, which
offers genetic testing, or genotyping, to people with hemophilia, a rare
genetic disorder that impairs the ability of the blood to clot properly.
Following the successful completion of an eleven site pilot program,
hemophilia treatment centers (HTCs) across the U.S., where the majority
of people with hemophilia receive care, can now participate in the
program and offer genotyping to the patients they serve.
My Life, Our Future is a partnership of the National
Hemophilia Foundation (NHF), the American
Thrombosis and Hemostasis Network (ATHN), Puget
Sound Blood Center (PSBC), and Biogen
Idec (NASDAQ: BIIB). Through genotyping, it is possible to identify
the specific DNA mutation(s), or change(s), responsible for a persons
hemophilia and provide potentially useful information about his/her
bleeding severity or risk for inhibitors, a major complication of
hemophilia that involves an immune response to treatment. Through My
Life, Our Future, participants can also contribute their data and
samples to a secure central research repository, which can serve as a
roadmap to greater scientific understanding of the disorder.
My Life, Our Future is a potential opportunity to shape the
future of hemophilia treatment and care, said Val Bias, chief executive
officer, NHF. I urge all people with hemophilia to participate; by
enrolling at a participating HTC, they have a chance to learn more about
their disorder today while furthering scientific advances tomorrow.